GE Healthcare Technologies Inc. (GEHC)

Over the past six months, GEHC's share price has underperformed the S&P 500 Index by -11.53%. As of June 27, 2025, the stock closed at $74.38. On June 13, 2025, the share price was $72.25, a decline of 6.83% from June 17, 2024, when it was $77.55. The stock has traded below its 200-day moving average of $80.91, indicating a potential recovery after recent dips. The Relative Strength Index (RSI) at 71.93 suggests the stock is nearing overbought conditions. Recent events include UBS upgrading its outlook for GE HealthCare from Sell to Neutral on May 5, 2025, the Annual Shareholders Meeting on May 25 and 28, 2025, attendance at the Goldman Sachs Global Healthcare Conference on June 10, 2025, and news regarding advancements in theranostics and AI tools. Additionally, GE HealthCare priced a secondary offering of shares on November 7, 2024, and entered a multi-year strategic partnership with Sutter Health on January 14, 2025.

GE HealthCare's business model benefits from strong and consistent demand across its segments due to long-term healthcare trends like aging populations. The company's book-to-bill ratio of 1.09 indicates that demand substantially exceeds its current fulfillment capacity, leading to a 10% increase in orders compared to the previous year. The company's "Digital Twin" technology helps hospitals forecast and prepare for seasonal surges proactively, suggesting that there can be variations in demand for hospital services that GE HealthCare's solutions address. The company also faces risks related to controlling healthcare costs, which could impact product demand.

GE Healthcare Technologies, Inc. is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator based in Chicago, Illinois. The company operates within the Healthcare sector, specifically in the Health Information Services industry, and its primary customers are hospitals and health networks. GE HealthCare's business is diversified across four major segments: Imaging (45% of revenue), Advanced Visualization Solutions (26% of revenue), Patient Care Solutions (16% of revenue), and Pharmaceutical Diagnostics (13% of revenue). Approximately half of GE HealthCare's revenue is recurring, derived from servicing, pharmaceutical diagnostics, and digital solutions.

GE HealthCare has a significant global presence, serving customers in over 160 countries with approximately 53,000 employees worldwide. The company conducts research and development in 18 countries and manufactures its products in 20 countries. Its sales are geographically diverse, with the United States accounting for 46% of revenue, EMEA for 26%, China for 12%, and the rest of the world for 17%. In 2023, 42% of its revenue came from the United States and 13% from China. Major regional operations and R&D centers are located in Buc, Helsinki, Kraków, Budapest, Yizhuang, Hino & Tokyo, and Bangalore.

GE HealthCare is recognized as a leading global medical technology and digital solutions innovator, emphasizing its commitment to sustainable innovation and aiming for net-zero emissions by 2050. In 2023, the company reduced its overall greenhouse gas emissions by 13% and recovered 7,375 imaging, ultrasound, and surgery machines, leading to over 15 million pounds of reused and recycled material. While older articles highlight past controversies from when GE Healthcare was part of General Electric, recent news focuses on product innovations and strategic partnerships.

GE HealthCare Technologies Inc. has a significant institutional ownership, with approximately 61.98% to 89.59% of the company's stock owned by institutional investors, 0.23% owned by insiders, and 10.18% to 27.61% by public companies and individual investors. Major institutional owners include Vanguard Group Inc., Capital Research Global Investors, BlackRock, Inc., State Street Corp, Dodge & Cox, Geode Capital Management, Llc, INVESTMENT CO OF AMERICA Class A, Vanguard Total Stock Market Index Fund Investor Shares and GROWTH FUND OF AMERICA Class A.